Inscripta raises $125M in Series D financing to accelerate commercialization of digital genome engineering platform

Inscripta raises $125M in Series D financing to accelerate commercialization of digital genome engineering platform

BOULDER -- Inscripta, Inc . announced it raised $125 million in a Series D financing with support from existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin... Read More

Wednesday December 11, 2019 0 comments Tags: Boulder, Inscripta, Paul Conley, Kevin Ness

Inscripta launches first benchtop platform for genome engineering

Inscripta launches first benchtop platform for genome engineering

BOULDER -- Inscripta, Inc. announced the launch of the Onyx Digital Genome Engineering platform, the worlds first fully automated benchtop instrument for genome-scale engineering. The... Read More

Wednesday October 9, 2019 0 comments Tags: Boulder, Inscripta, Kevin Ness

Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

Inscripta: MAD7 CRISPR enzyme widely adopted in first year of availability

BOULDER -- Inscripta , a gene-editing technology company, today announced MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in... Read More

Thursday December 20, 2018 0 comments Tags: Boulder, Inscripta, MAD7, Kevin Ness

Inscripta hires Jason Gammack as first chief commercial officer

Inscripta hires Jason Gammack as first chief commercial officer

BOULDER -- Gene-editing technology company Inscripta today announced the hiring of Jason T. Gammac kas the company's first chief commercial officer. Gammack, a 25-year veteran of life... Read More

Friday November 2, 2018 0 comments Tags: Boulder, Inscripta, Jason Gammack, Kevin Ness